SEATTLE — Immunex Corp. gained approval for doctors to use a cancer drug as the first treatment for people with crippling late-stage multiple sclerosis.
The Food and Drug Administration approved mitoxantrone, to be sold under the name Novantrone, for patients with the secondary progressive form of the disease. In these patients, the drug reduced the frequency of flare-ups and slowed the progression of disability. The FDA warned, however, that some patients using the drug can develop serious heart problems, a risk that increases with the cumulative doses.
Talk to us
- You can tell us about news and ask us about our journalism by emailing firstname.lastname@example.org or by calling 425-339-3428.
- If you have an opinion you wish to share for publication, send a letter to the editor to email@example.com or by regular mail to The Daily Herald, Letters, P.O. Box 930, Everett, WA 98206.
- More contact information is here.